218 related articles for article (PubMed ID: 31190905)
21. Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program.
Beauvais D; Robin C; Thiebaut A; Alain S; Coiteux V; Ducastelle-Lepretre S; Marçais A; Ceballos P; Xhaard A; Redjoul R; Nguyen S; Brissot E; Joris M; Turlure P; Rubio MT; Chevallier P; Bénard N; Liautard C; Yakoub-Agha I
J Clin Virol; 2022 Mar; 148():105106. PubMed ID: 35182958
[TBL] [Abstract][Full Text] [Related]
22. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
Cho JC; Le AD; Locke SC
Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
[TBL] [Abstract][Full Text] [Related]
23. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
Hill JA; Zamora D; Xie H; Thur LA; Delaney C; Dahlberg A; Pergam SA; Leisenring WM; Boeckh M; Milano F
Blood Adv; 2021 Aug; 5(16):3113-3119. PubMed ID: 34402885
[TBL] [Abstract][Full Text] [Related]
24. Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan.
Hiraishi I; Ueno R; Watanabe A; Maekawa S
Clin Drug Investig; 2021 Dec; 41(12):1075-1086. PubMed ID: 34784011
[TBL] [Abstract][Full Text] [Related]
25. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review.
El Helou G; Razonable RR
Infect Drug Resist; 2019; 12():1481-1491. PubMed ID: 31239725
[TBL] [Abstract][Full Text] [Related]
26. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Ljungman P; Schmitt M; Marty FM; Maertens J; Chemaly RF; Kartsonis NA; Butterton JR; Wan H; Teal VL; Sarratt K; Murata Y; Leavitt RY; Badshah C
Clin Infect Dis; 2020 Apr; 70(8):1525-1533. PubMed ID: 31179485
[TBL] [Abstract][Full Text] [Related]
27. Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study.
Royston L; Royston E; Masouridi-Levrat S; Vernaz N; Chalandon Y; Van Delden C; Neofytos D
Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33921218
[TBL] [Abstract][Full Text] [Related]
28. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].
Lázaro y de Mercado P; Figueras Aloy J; Doménech Martínez E; Echániz Urcelay I; Closa Monasterolo R; Wood Wood MA; Fitch Warner K
An Pediatr (Barc); 2006 Oct; 65(4):316-24. PubMed ID: 17020726
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation.
Li WW; Zhang YM; Shen MZ; Mo XD
Blood Sci; 2024 Jan; 6(1):e00178. PubMed ID: 38213825
[TBL] [Abstract][Full Text] [Related]
30. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
Hecke SV; Calcoen B; Lagrou K; Maertens J
Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
[TBL] [Abstract][Full Text] [Related]
31. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States.
Blumberg EA; Hauser IA; Stanisic S; Mueller E; Berenson K; Gahlemann CG; Humar A; Jardine AG
Transplantation; 2010 Dec; 90(12):1420-6. PubMed ID: 21063245
[TBL] [Abstract][Full Text] [Related]
32. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
33. [Cytomegalovirus infections following allogeneic hematopoietic stem cell transplantation: prophylaxis and treatment].
Katayama Y; Iwato K
Rinsho Ketsueki; 2019; 60(6):635-645. PubMed ID: 31281156
[TBL] [Abstract][Full Text] [Related]
34. Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease.
Wolfe D; Zhao Q; Siegel E; Puto M; Murphy D; Roddy J; Efebera Y; Tossey J
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771734
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy.
Coppola A; D'Ausilio A; Aiello A; Amoresano S; Toumi M; Mathew P; Tagliaferri A;
Haemophilia; 2017 May; 23(3):422-429. PubMed ID: 28181369
[TBL] [Abstract][Full Text] [Related]
36. [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation].
Kawalec P; Holko P; Szkultecka-Debek M; Paszulewicz A; Boratyńska M; Głyda M; Ignacak E; Maks J; Russel-Szymczyk M; Kaweczyńska-Lasoń A
Pol Merkur Lekarski; 2013 Jun; 34(204):332-8. PubMed ID: 23882930
[TBL] [Abstract][Full Text] [Related]
37. Letermovir safety and efficacy for cytomegalovirus prophylaxis in adult Japanese kidney transplant recipients: a multicenter, open-label, noncomparative Phase 3 study.
Ishida H; Goto N; Imamura R; Sasaki H; Unagami K; Futamura K; Murata Y; Oshima N; Eto T; Haber B
Clin Exp Nephrol; 2024 Apr; ():. PubMed ID: 38615067
[TBL] [Abstract][Full Text] [Related]
38. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.
Chen K; Cheng MP; Hammond SP; Einsele H; Marty FM
Blood Adv; 2018 Aug; 2(16):2159-2175. PubMed ID: 30154125
[TBL] [Abstract][Full Text] [Related]
39. Letermovir and tacrolimus interaction effects in hematopoietic cell transplantation recipients receiving moderate cytochrome P450 3A4 inhibitors for antifungal prophylaxis.
Malespini J; Lei M; Tavares E; Hammond SP; Chen YB; Luk SO; DeFilipp Z
J Oncol Pharm Pract; 2023 Oct; 29(7):1574-1579. PubMed ID: 36398324
[TBL] [Abstract][Full Text] [Related]
40. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Gagelmann N; Ljungman P; Styczynski J; Kröger N
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2101-2109. PubMed ID: 29777868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
